Myndscope works to commercialize disease-modifying medicine in neurodegenerative diseases. Myndscope has several candidates in their early stage of development. At the moment, we are past the drug screening and discovery stages, and are currently moving the candidates through target optimization. Preliminary efficacy studies were completed in vivo as part of the strategy validation processes. Our next steps are dose determining studies, toxicity evaluations, and elucidating the mechanism of actions more in detail.
Neuroscience at its best